https://www.selleckchem.com/products/liproxstatin-1.html Repeated intraperitoneal injection of rhRSPO1 was feasible and well tolerated. At 7 days, intestinal epithelial proliferation was increased by rhRSPO1. At 14 days, SBS+rhRSPO1 fish lost significantly less weight than SBS+PBS fish. Measurements of intestinal surface area were not increased by rhRSPO1 administration but immunofluorescent staining for β-catenin and gene expression for was increased. Intraperitoneal injection of rhRSPO1 decreased weight loss in SBS zebrafish with increased β-catenin+cells and expression at 14 days, indicating improved weight maintenance might result from increased activation of the canonical Wnt pathway. Intraperitoneal injection of rhRSPO1 decreased weight loss in SBS zebrafish with increased β-catenin + cells and cyclin D1 expression at 14 days, indicating improved weight maintenance might result from increased activation of the canonical Wnt pathway. The aim of this study was to assess the marketing status of the new paediatric medicinal products listed in the 10-year report as initially authorised between 2007 and 2016, reflecting the product availability in four Nordic countries. This is a cross-sectional study. Analysis of the national medicine agency's databases in Denmark, Finland, Norway and Sweden. New medicinal products with paediatric indications and new paediatric formulations listed in the Annex of European Medicines Agency's EU Paediatric Regulation 10-year report. The products were classified according to national marketing status between January 2019 and March 2019, whether a product was authorised and whether the product was marketed. The percentages of the new medicinal products with paediatric indications and new paediatric formulations having a valid marketing authorisation and being marketed, both in terms of the sums of all countries and separately for each country. Across the four countries, 21%-32% (16/76-24/76) of the new medicinal products were not marke